Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future

Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocyt...

Descripción completa

Detalles Bibliográficos
Autores: Valent, Peter, Akin, Cem, Hartmann, Karin, Nilsson, Gunnar, Reiter, Andreas, Hermine, Olivier, Sotlar, Karl, Sperr, Wolfgang R., Escribano, Luis, George, Tracy I., Kluin-Nelemans, Hanneke C., Ustun, Celalettin, Triggiani, Massimo, Brockow, Knut, Gotlib, Jason, Orfao, Alberto, Schwartz, Lawrence B., Broesby-Olsen, Sigurd, Bindslev-Jensen, Carsten, Kovanen, Petri T., Galli, Stephen J., Austen, K. Frank, Arber, Daniel A., Horny, Hans-Peter, Arock, Michel, Metcalfe, Dean D.
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2017
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/169289
Acceso en línea:http://hdl.handle.net/10261/169289
Access Level:acceso abierto
Palabra clave:Mast cells
Midostaurin
Prognostication
Tryptase
KIT D816V
Mastocytosis
Descripción
Sumario:Mastocytosis is a term used to denote a heterogeneous group of conditions defined by the expansion and accumulation of clonal (neoplastic) tissue mast cells in various organs. The classification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors. On the basis of histomorphologic criteria, clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia. The clinical impact and prognostic value of this classification has been confirmed in numerous studies, and its basic concept remains valid. However, refinements have recently been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis. In addition, new treatment options are available for patients with advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase inhibitors directed against KIT D816V and other key signaling molecules. Our current article provides an overview of recent advances in the field of mastocytosis, with emphasis on classification, prognostication, and emerging new treatment options in advanced SM.

Similares en LA Referencia